Widespread application of NGS due to its reliability over conventional methods for sequencing is anticipated to provide avenues for a steady increase in adoption resulting in an enhanced market penetration into the field of medical oncology over the coming years.
Rising adoption of advanced genetic sequence analysis in various fields of clinical research due to the concurrent fall in base pair mapping costs is a high impact rendering factor in favor of stable growth. A number of cancer researchers have considered the significant importance of this technology in oncology and invested efforts for the development of bioinformatics algorithms to be utilized for cancer screening and test development. A number of oncologists believe that in the coming seven years, next-generation sequencing combined with companion diagnostics can be expected to play a major role in personalized diagnostics and therapeutics and thus significant increase in demand for application of these platforms in the field can be anticipated to revolutionize the market.
NGS enabled cataloging of the genomic landscape of thousands of oncogenes is anticipated to facilitate investigation of the underlying pathway behind the diseases. Furthermore, ongoing technological advancement of in silico algorithms is likely to influence the growth in market revenue. For instance, the introduction of workflow management systems solutions like Galaxy and Chipster that offer data analysis methods, are expected to further drive demand in this sector.
U.S. clinical oncology NGS market, 2013 - 2024 (USD Million)
Strategic initiatives undertaken by the U.S. government for R&D in oncology are also projected to drive growth. Grants and loans have also been provided by the U.S government and funding bodies to narrow down the gap between genomic sequence analysis platform development and their implementation in oncology research. Furthermore, cancer-associated expenditures are anticipated to rise significantly thereby influencing the adoption of second-generation sequencing platforms for the purpose of diagnostic monitoring and theranostics applications. The most significant bottleneck in the workflow of this technology includes time-consuming interpretation of data generated in abundant amounts once the genome is sequenced, which offers innumerable opportunities for commercial service providers to develop feasible solutions with faster turnaround times.
Targeted sequencing and re-sequencing accounted for the largest share of revenue generated in 2015. A significant subset or region of the genetic sequence of isolated genes is used for high coverage genetic expression analysis. This technology is estimated to witness a rise in demand as it enables even higher throughput at a reduced price per sample. Targeted RNA sequencing provides a platform that offers enhanced coverage for robust transcript assembly, accurate gene quantification, and sensitive gene discovery. Usage of next-generation sequencing also provides broad coverage of expressed genes due to the wide dynamic range of eukaryotic transcriptomes which results in robust isoform assembly. Application of WGS technology for comparisons between tumor tissue and normal tissue is expected to experience considerable success in the next 7 years owing to the decreasing complexity in its implementation. Moreover, researchers believe that in the coming years, WGS may enable everyone to develop a personalized treatment plan. In addition, introducing new tools such as NextSeq and MiniSeq platforms are likely to enhance the ability for a broad spectrum of research labs with varying sequencing needs.
The transition in base pair mapping methods from single gene to multi-parallel genomic analysis is potentially the most influencing factor for augmentation of the market in the coming years. Of the different steps involved in the high throughput sequencing method, process flow related to genetic sequencing held the largest share owing to the fact that platforms such as MiSeq, HiSeq, and SoLid are highly capital intensive to procure. The expected increase in adoption and usage rates of WGS has spurred the demand for such platforms in clinical oncology and hence this sector is projected to witness surging growth throughout the forecast period.
Owing to widespread applications of NGS, there has been a significant rise in the usage rate of multigene sequencing and further expected development will provide novel avenues of applications particularly for understanding the functioning mechanisms of oncogenes. A wide range of end users including clinical research, pharma & biotech entities, academic research institutes, and hospitals & clinics undertake varying levels of clinical oncology using next-generation sequencing tech. Oncology R&D in academic institutes dominated the sector as a result of increasing awareness of advantages associated with the implementation of second-generation sequencing in academic and university-based research projects.
Some of the major participants of the market include Illumina Inc., Roche, Agilent Technologies, Knome Inc. Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd, Macrogen Inc., Life Technologies Corp, DNASTAR Inc, Exosome Diagnostics, Biomatters Ltd, CLC Bio, BGI, Qiagen NV, Perkin Elmer, Inc, Pacific Bioscience, Inc, Partek, Inc, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences, and Myriad Genetics. They are involved in capitalizing on data analysis requirements and need for more robust sequencing platforms through collaboration and funding deals between major and minor players.
For instance, In June 2015, Partek collaborated with Kennedy Krieger Institute and developed commercial software for analyzing chromosomal abnormalities in diseases such as bipolar disorder, autism spectrum disorder, and schizophrenia. This collaboration is anticipated to enhance the sale of Partek helping the market growth.
Second generation multi-parallel high throughput genetic sequencing, otherwise known as next-generation sequencing (NGS) has been a highly dynamic segment of healthcare-biotechnology over the past decade. With the enhanced capability of in-depth genomic investigation provided by the technology, researchers and scientists alike have been overwhelmed with its possible applications and the consequent probable breakthroughs in the field of healthcare that have become possible due to its introduction. Clinical oncology is a key application segment of NGS and with the ongoing developments related to oncogene analysis, this segment is expected to draw considerable attention over the forecast period. The report is designed to provide a comprehensive overview of the U.S. NGS-based clinical cancer R&D market to biopharmaceutical entities, NGS-based research institutes. It examines the extent of penetration of NGS based R&D for clinical oncology by providing estimates and forecasts for the years 2013 to 2024.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.